Natural substances and Alzheimer's disease: From preclinical studies to evidence based medicine
- 31 May 2012
- journal article
- review article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1822 (5), 616-624
- https://doi.org/10.1016/j.bbadis.2011.09.004
Abstract
No abstract availableKeywords
Funding Information
- Fondi Ateneo
This publication has 120 references indexed in Scilit:
- Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotectionNeuroscience, 2011
- Ginkgo biloba for Preventing Cognitive Decline in Older AdultsA Randomized TrialJAMA, 2009
- RETRACTED: Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivoBiochemical Pharmacology, 2009
- Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesisActa Neuropathologica, 2009
- Ginkgo biloba for Prevention of DementiaA Randomized Controlled TrialJAMA, 2008
- Protective effect of quercetin in primary neurons against Aβ(1–42): relevance to Alzheimer's diseaseThe Journal of Nutritional Biochemistry, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairmentFree Radical Biology & Medicine, 2007
- Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane)Free Radical Biology & Medicine, 2007
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005